Advancing the Cholangiocarcinoma & Myeloid Lymphoid Neoplasm Patient Journey
Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
Login to view comments.
Click here to Login
Advancing the Cholangiocarcinoma & Myeloid Lymphoid Neoplasm Patient Journey